Cartesian Therapeutics (RNAC) Equity Average: 2016-2025
Historic Equity Average for Cartesian Therapeutics (RNAC) over the last 9 years, with Sep 2025 value amounting to -$19.2 million.
- Cartesian Therapeutics' Equity Average rose 61.90% to -$19.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$19.2 million, marking a year-over-year increase of 61.90%. This contributed to the annual value of -$223.5 million for FY2024, which is 29.05% down from last year.
- Cartesian Therapeutics' Equity Average amounted to -$19.2 million in Q3 2025, which was down 57.80% from -$12.2 million recorded in Q2 2025.
- Cartesian Therapeutics' Equity Average's 5-year high stood at $89.4 million during Q4 2022, with a 5-year trough of -$278.5 million in Q1 2024.
- For the 3-year period, Cartesian Therapeutics' Equity Average averaged around -$41.8 million, with its median value being -$14.3 million (2025).
- Per our database at Business Quant, Cartesian Therapeutics' Equity Average slumped by 10,166.94% in 2021 and then soared by 4,615.96% in 2022.
- Over the past 5 years, Cartesian Therapeutics' Equity Average (Quarterly) stood at $1.9 million in 2021, then soared by 4,615.96% to $89.4 million in 2022, then tumbled by 312.52% to -$189.9 million in 2023, then soared by 98.41% to -$3.0 million in 2024, then spiked by 61.90% to -$19.2 million in 2025.
- Its Equity Average stands at -$19.2 million for Q3 2025, versus -$12.2 million for Q2 2025 and -$14.3 million for Q1 2025.